CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Adaptive Biotechnologies Corp is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Adaptive Biotechnologies Corp
1165 Eastlake Ave E
Phone: (206) 659-0067p:206 659-0067 SEATTLE, WA  98109  United States Ticker: ADPTADPT
Business Summary
Adaptive Biotechnologies Corporation is a commercial-stage biotechnology company. The Company is focused on harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its proprietary technologies to read the diverse genetic code of a patient’s immune system and understand precisely how the immune system detects and treats disease in that patient. It has business around two main areas: clinical assessment of minimal residual disease (MRD) in lymphoid malignancies and immune medicine (IM)-driven drug discovery and development. The MRD business focuses on the use of its highly sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. It comprises its clonoSEQ clinical diagnostic test, offered to clinicians, and its clonoSEQ assay, offered to biopharmaceutical partners, to advance drug development efforts (MRD Pharma).

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202412/31/2023YesYes--Yes

Industries
SIC Code Description
8731 Commercial physical and biological research
2835 In vitro and in vivo diagnostic substances
2836 Biological products, except diagnostic substances

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Executive Officer, Co-Founder Chad M.Robins 49 9/1/2009 9/1/2009
President, Chief Operating Officer JulieRubinstein 52 4/1/2023 2/1/2018
Co-Founder, Chief Scientific Officer Harlan S.Robins 50 9/1/2009 9/1/2009
10 additional Officers and Directors records available in full report.

Subsidiaries
Business Name Address City State/Province Country
Sequenta, Inc. 400 East Jamie Court South San Francisco CA United States

Business Names
Business Name
Adaptive Biotechnologies B.V. Netherlands
ADPT
Digital Biotechnologies, Inc. Delaware
Sequenta, Inc.

General Information
Number of Employees: 709 (As of 12/31/2023)
Outstanding Shares: 147,579,486 (As of 11/4/2024)
Shareholders: 85
Stock Exchange: NASD
Federal Tax Id: 270907024
Fax Number: (206) 659-0667


Copyright © 2024 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Wednesday, November 20, 2024